A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders
A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders
复制标题
DOI：
10.1089/104454602760386932
复制
发表时间：
2002-09-01
影响因子：
1.9
通讯作者：
Nicolson, R
中科院分区：
文献类型：
--
作者：
Couturier, JL;Nicolson, R
虽然选择性5 -羟色胺再摄取抑制剂已被用于治疗患有广泛性发育障碍（pdd）的儿童和青少年的攻击和焦虑症状，但没有关于西酞普兰在这一人群中使用的公开报道。本研究的目的是检查西酞普兰对一组患有pdd的儿童和青少年的益处和不良影响。目标行为包括攻击性、焦虑、刻板印象和专注。17例pdd患者（14例患有自闭症，3例患有阿斯伯格综合症）（平均年龄= 9.4 +/- 2.9岁，范围4-15岁）接受西酞普兰治疗至少2个月（平均治疗时间= 7.4 +/- 5.3个月，范围1-15个月）。治疗开始时低剂量（每天5mg），并根据耐受性和需要每周增加5mg。平均最终剂量为19.7±7.8 mg（范围5-40 mg）。结果是基于临床医生和家长之间的共识，使用临床整体印象量表的改善项目作为指导。10名（59%）儿童被认为在目标行为方面有很大改善或非常改善。pdd的核心症状（社交、沟通）没有临床显著改善。西酞普兰。总体上耐受性良好，尽管4名患者出现了限制治疗的不良反应：2名患者躁动加剧，1名患者失眠，1名患者可能抽搐。这一系列病例的结果表明，西酞普兰。对某些干扰行为有有益的影响。与pdd相关，几乎没有副作用。有必要进行对照试验。
Although selective serotonin reuptake inhibitors have been used to treat symptoms of aggression and anxiety in children and adolescents with pervasive developmental disorders (PDDs), there are no published reports of the use of citalopram in this population. The purpose of this study was to examine the benefits and adverse effects of citalopram in a group of children and adolescents with PDDs. Target behaviors included aggression, anxiety, stereotypies, and preoccupations. Seventeen patients with PDDs (14 with autistic disorder, three with Asperger's disorder) (mean age = 9.4 +/- 2.9 years; range 4-15 years) were treated with citalopram for at least 2 months (mean duration of treatment = 7.4 +/- 5.3 months; range 1-15 months). Treatment was initiated at a low dose (5 mg daily) and was increased by 5 mg weekly as tolerated and as necessary. The mean final dose was 19.7 +/- 7.8 mg (range 5-40 mg). Outcome was based on a consensus between clinician and parents, using the Improvement item of the Clinical Global Impressions Scale as a guide. Ten (59%) children were judged to be much improved or very much improved regarding target behaviors. Core symptoms of PDDs (social interactions, communication) did not show clinically significant improvement. Citalopram. was generally well tolerated, although four patients developed treatment-limiting adverse effects: two with increased agitation, one with insomnia, and one with possible tics. The results of this case series suggest that citalopram. has beneficial effects on some interfering behaviors. associated with PDDs with few adverse effects. Controlled trials are warranted.